Co-Diagnostics (CODX) Stock Price, Quote, News & History | Benzinga

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD82,718.59+0.19%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

Co-Diagnostics Inc (CODX) Stock Price, Quote, News & History

CODXNASDAQ

Trade with Public

Trade with Public

$1.12

0.032.75%

Last update: Oct 9, 4:00 PM

$1.09

N/A

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$1.09

Close

$1.12

Volume / Avg.

103.77K / 322.02K

Day Range

$1.12 - $1.12

52 Wk Range

0.91 - 46.50

Market Cap

$7.61M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

4.44%

Days to Cover

2.35

Recent Co-Diagnostics Inc News

Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)

Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus

Rishabh Mishra

United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday

Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.

Avi Kapoor

Merck-Backed Lab Gets $8.5 Million to Fast-Track a Vaccine for a Rapidly Spreading Ebola Outbreak

Merck and Wellcome-backed Hilleman will manufacture Bundibugyo Ebola vaccine doses for clinical trials with up to $8.5M in CEPI funding.

Tanya Rawat

EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola Test

Co-Diagnostics advances its Ebola testing capabilities, sending Bundibugyo virus test kits for evaluation and completing a new assay study.

Vandana Singh

Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket

Forte Biosciences shares rose 38.9% to $76.10 in pre-market trading after argenx SE announced plans to acquire the company for $77 per share.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-27.10M

Investing Cash Flow (TTM)

1.54M

Financing Cash Flow (TTM)

18.10M

Free Cash Flow (TTM)

-27.47M

Capital Expenditure (TTM)

-367.37K

Net Change in Cash (TTM)

-7.47M

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.93M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.67

PB Ratio (TTM)

0.60

Earnings Yield % (TTM)

-2375.23%

Earnings Yield % (FWD)

-76.15%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.82

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$3.65M

Debt to Equity

0.14

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-